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Aims: We examined the preoperative serum levels of sialyl 
Lewisa (CA19-9) and carcinoembryonic antigen (CEA) in 
262 colorectal cancer patients, in order to clarify whether 
or not the prognostic value of CA19-9 after curative sur-
gery is superior to that of CEA. 
Patients and Methods: The patients were divided into two 
groups: low or high antigen groups (higher or lower than 
a selected diagnostic-based cut-off value). For evaluation of 
the prognostic value of CA19-9 and CEA, the disease-free 
interval was studied. 
Results: The disease-free interval of patients with a high 
serum levels of CA19-9 or CEA was significantly shorter 
than for those patients with a low serum level of the par-
ticular antigen (P<0.0001 and P=0.0009, respectively). The 
disease-free interval of patients with stage I/II tumors who 
had a high CA19-9 level was significantly shorter than in 
those patients with stage I/II tumors with low CA19-9 levels 
(P=0.0020). In contrast, the disease-free interval of pa-
tients with stage I/II tumors who had a low or high CEA 
level did not differ. Cox s regression analysis revealed that 
a high serum level of CA19-9 or CEA was an independent 
predictor for short disease-free interval after curative sur-
gery, separate from stage (Hazard ratio=2.65 or 1.68, re-
spectively, versus a low serum level of each respective anti-
gen) . 
Conclusions: These data suggest that the preoperative serum 
level of CA19-9 was a stronger prognostic factor after 
curative surgery than CEA. Furthermore, in contrast to 
CEA, CA19-9 provides more prognostic information than 
that obtained by conventional staging methods in patients 
with stage I/II tumors.
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Introduction
 Carbohydrate antigen 19-9 (CA 19-9) and Carcino-
ebryonic antigen (CEA) have been well recognized, 
and are widely used as tumor markers for colorectal 
caner."" The structure of CA19-9 was identified by 
Magnani et al. as a ganglioside-containing sialylated 
lacto-N-fucopentaose II (sialyl Lewisa ), structurally re-
lated to the Lewisa blood-group substance.'," CA 19-9 
binds to the endothelial cell-surface receptors E-selectin 
and P-selectin.5) Thus, cells expressing CA 19-9 adhere to 
endothelial cells that had been activated by some 
cytokine6' Such molecular function supports the idea 
that CA 19-9 may actually play a role in the adhesion of 
cancer cells to endothelial cells, resulting in hematogenous 
metastasis.") The increased expression of CA 19-9 in 
tumors, as demonstrated by immunohistochemistry, is 
associated with poor prognosis in colorectal cancer pa-
tients after surgery.10) 
 Such oncologically-induced carbohydrate modifica-
tions, however, may not be limited to the tumor s pri-
mary site."' Filella et al.') reported that the preopera-
tive serum level of CA 19-9 provided more prognostic 
information than could be obtained by conventional 
staging methods in colorectal cancer patients. In addi-
tion, the prognostic significance of CEA was not inde-
pendent of Dukes classification.') However, to date, 
CEA is the most commonly used tumor maker in pa-
tients with the colorectal cancer. It s use as an early 
diagnostic index for recurrence during follow-up after 
radical surgery has been well established by several 
authors."-") Therefore, the aim of this study is to
clarify whether or not the prognostic value of CA19-9 
is superior to that of CEA in colorectal cancer patients.
Patients and Methods
 Preoperative serum levels of CA 19-9 and CEA were 
measured in 262 colorectal cancer patients (155 male 
and 107 female) who underwent attempted curative 
resections at Nagasaki University Hospital from January 
1990 to December 1995. The median age of patients 
studied was 65.0 years (range, 23 - 90). Patients with 
more than one carcinoma of the colon (synchronous 
or metachronous) were excluded from this study. In 
the studied patients, there was no evidence of other 
organ malignancies, and no patients had been given 
preoperative treatment with anticancer drugs. Patients 
who died within 30 postoperative days were not in-
cluded in this study. 
 One hundred and sixty tumors were localized in the 
colon and 102 tumors were localized in the rectum. 
The surgically resected specimens from the 262 colo-
rectal cancer patients were fixed in 10% formaldehyde 
and embedded in paraffin. The sections of the resected 
specimens were stained with hematoxylin and eosin. 
The American Joint Committee on Cancer (AJCC ) 
Classification and Stage grouping was used to classify 
the tumors.") Each tumor was histopathologically clas-
sified according to its histology using the World 
Health Organization criteria presented by Jass and 
Sobin16) : 80 tumors were classified as well-differentiated 
adenocarcinomas, 155 tumors as moderately differenti-
ated adenocarcinomas, 20 tumors as poorly differenti-
ated adenocarcinomas, and 7 tumors as mucinous car-
cinomas. The 262 patients included 38 patients in stage 
I, 130 in stage II, and 94 in stage III. 
 All patients underwent standard follow-up examina-
tions, including laboratory testing every 3 months. 
The median length of follow-up was 1847 days (range, 
72-3154 days). Of the 262 patients, 171 patients are 
currently alive with no evidence of recurrent disease, 
while 4 patients are alive with recurrent disease at the 
time of this writing (i.e. December 1999). Recurrences 
of colorectal cancer followed by death occurred in 63 
patients, and 24 patients died of different diseases 
with no evidence of colorectal tumor.
Measurement of the serum levels of antigens
 In order to detect the presence of circulating cancer 
markers, blood was obtained from the patients venous 
circulation after an overnight fast. The blood samples
were separated immediately by centrifugation and the 
remaining blood sera were stored at -800C until use. 
The serum levels of CA19-9 and CEA were measured 
in the Otsuka Assay Laboratory (Tokushima, Japan) 
using commercially available radioimmunoassay kits: 
specifically, the Centocor CA 19-9 RIA kit"' (Centocor, 
Malvern, PA, USA) and the CEA Roche 2 kit's) 
(Nippon Roche K.K., Tokyo, Japan), respectively. The 
data obtained were based on the simultaneous assay of 
these two antigens using the same set of sera. The cut-off 
values recommended by the manufacturers for diagnos-
tic use were 37 U/ml for CA 19-9 and 2.5 ng/ml for CEA 
17.18) For each antigen
, we classified the patients into two 
groups: a high antigen group, with a serum antigen con-
centration greater than the selected cut-off value, and 
a low antigen group, with less than the cut-off value.
Statistical analysis
 For univariate statistical analysis, the X 2 test or 
Fisher's exact probability test for categorical data was 
used. For evaluation of the prognostic value of CA 19-9 
and CEA, the disease-free interval in the 262 patients 
was studied. The effect of each variable upon the 
disease-free interval was calculated according to the 
Kaplan-Meier method,") and differences between sur-
vival curves were tested for significance using the log-
rank test.20) 
 Multivariate analysis was performed with a Cox's 
proportional hazard regression model in order to as-
sess the effects of different variables on patient." The 
serum levels of CA19-9 and CEA were compared with 
the stage that is generally used in colorectal cancer 
patient management and well-supported in the litera-
ture. 15) All tests were two-tailed and a P value of less 
than 0.05 was considered to be significant.
Results
Comparison of stage between low antigen group and 
high antigen group 
 Of the 262 patients, the high antigen groups encom-
passed the following patients and percentages: 52 
(19.9%) for CA 19-9 and 92 (35.1%) for CEA. The dis-
tribution of CA 19-9 and CEA according to the AJCC 
stage grouping is shown in Table 1. The high CEA 
group had a more advanced stage than the low CEA 
group (P=0.0026), although there was no difference in 
stage between the low CA19-9 group and the high CA19-
9 group.
Table 1. Distribution of CA19-9 and CEA according to AJCC 
stage grouping.
Table 2. Prognostic variables for survival in Cox s regression 
analysis.
         No. of Carcinoma (%) No. of Carcinoma (%) 
          Low High Low CEA High CEA
          CA19-9 CA19-9 group group
          group group (n=170) (n=92) 
         (n=210) (n=52) P value P value 
Stage 0.0965 0.0026 
 
I 35 (16.7) 3(5.8) 34 (20.0) 4(4.4) 
 II 104 (49.5) 26 (50.0) 80 (47.1) 50 (54.4) 
 III 71 (33.8) 23 (44.2) 56 (32.9) 38 (41.3)
Variable Categories Hazard ratio (95% CI*) P value 
Stage I 1 
                      II 5.07 0.67-37.99 0.1140 
                     111 18.81 2.57-137.42 0.0038
Serum CA19-9 status Low 1 
                     High 2.65 1.59-4.41 0.0002 
Serum CEA status Low 1 
                     High 1.68 1.02-2.78 0.0410
* CI
, Confidence interval.
Comparison of disease-free interval after surgery be-
tween low antigen group and high antigen group pa-
tients
 Figure 1 shows the disease-free interval of patients 
with colorectal cancer according to the results of pre-
operative CA 19-9 and CEA levels. Patients with high 
serum levels of CA 19-9 and CEA had shorter disease-
free intervals than those with low serum levels of 
those respective antigen (P<0.0001 and P=0.0009, re-
spectively) 
 Figures 2 and 3 show the prognostic evaluations of 
CA19-9 and CEA serum levels subdivided according to 
AJCC stage grouping. The disease-free interval of pa-
tients with stage I/II tumors who had high CA19-9 lev-
els was significantly shorter than that noted in patients 
with low CA19-9 levels (P=0.0020), although the 
disease-free interval of patients with stage I/II disease 
who had either low or high CEA levels did not differ. 
The disease-free interval of patients with stage III dis-
ease who had high serum levels of CA19-9 or CEA was 
significantly shorter than the interval noted in patients 
with low serum levels of the respective antigens (P 
=0 .0008 or P=0.0019, respectively).
Prognostic value of serum antigen level
 A multivariate Cox's regression analysis was used in 
order to select the variables having the correlation 
with disease-free interval. The variables, i.e. serum 
CA 19-9 status or serum CEA status, were each inde-
pendent prognostic factors for the disease-free interval 
of patients after curative surgery, separate from stage. 
The hazard ratios of high serum levels of CA 19-9 or 
CEA versus low serum levels of the respective anti-
gens were 2.65 or 1.68, respectively (Table 2).
Fig 1. Disease-free interval after curative surgery for patients 
with colorectal cancer according to preoperative serum levels 
of CA 19-9 (top) and CEA (bottom).
Figure 2. Disease-free interval after curative surgery for pa-
tients with stage I/II tumors according to preoperative serum 
levels of CA 19-9 (top) and CEA (bottom).
Discussion
 The current study reveals that preoperative serum 
level of CA19-9 is a stronger prognostic factor after 
curative surgery than the preoperative serum level of 
CEA. In particular, the preoperative serum level of 
CA 19-9 in patients with stage I/II tumors provided ad-
ditional information for allocating these patients into 
groups of either low or high risk of recurrence, in con-
trast to serum levels of CEA. 
 The prognostic value of the preoperative serum 
CA 19-9 level has been reported in patients with colo-
rectal cancer.',"` Filella et al.') reported the prognos-
tic value of CA19-9 and CEA based on the disease-free 
interval after curative surgery in 162 colorectal cancer 
patients. The prognostic value of these serum markers 
are as follows: (i) CA 19-9 provides more prognostic
Figure 3. Disease-free interval after curative surgery for pa-
tients with stage III tumors according to preoperative serum 
levels of CA19-9 (top) and CEA (bottom).
information than conventional staging methods (Dukes 
classification). In patients with Dukes C tumors, addi-
tional information is obtained for the allocation of 
these patients into groups of either low or high risk of 
recurrence; (ii) the prognostic significance of CEA is 
not independent of Dukes classification, according to 
multivariate analysis. 
 The current study also reveals that CA 19-9 provides 
more prognostic information than conventional staging 
methods. In fact, the preoperative serum levels of 
CA 19-9 in patients with stage 1/11 or III tumors pro-
vides additional information for allocating these pa-
tients into groups of recurrence risk (either low or 
high risk). However, in the report of Filella et al.,') the 
prognostic value of CA 19-9 in patients with Dukes B 
tumors is not revealed. The difference between the 
current study and Filella et al. s report ') may be due
to the number of patients studied. A total of 168 pa-
tients with stage I/II tumors in our series represents 
82 patients more than in the Filella et al. s report.') 
 In the AJCC Cancer Staging Manual, serum CEA 
level, as well as stage and histologic type, is proposed 
as an independent prognostic factor for colorectal can-
cer patients.") Many studies supported this proposal 
•2,24,25) The current study also reveals that the preopera-
tive serum level of CEA is an independent prognostic 
factor after curative surgery, separate from stage. 
Filella et al.') has reported that the prognostic signifi-
cance of CEA is not independent of Dukes classifica-
tion, according to multivariate analysis. We feel that 
small number of patients in the Filella et al. s report') 
may explain the difference between two studies. 
 In conclusion, the preoperative serum level of CA 19-
9 was a stronger prognostic factor after curative sur-
gery than the serum CEA level. In addition, CA 19-9 
provides more prognostic information than is other-
wise obtained by conventional staging methods.
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